Larimar Therapeutics
LRMR
49 hedge funds and large institutions have $27.7M invested in Larimar Therapeutics in 2019 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 15 closing their positions.
63% more capital invested
Capital invested by funds: $17M → $27.7M (+$10.7M)
0.44% more ownership
Funds ownership: 5.12% → 5.57% (+0.44%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 51 → 49 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$1.82M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$796K |
| 3 |
O
OrbiMed
New York
|
+$654K |
| 4 |
6CM
683 Capital Management
New York
|
+$295K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$277K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.44M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$490K |
| 3 |
BlackRock
New York
|
-$290K |
| 4 |
Goldman Sachs
New York
|
-$205K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$197K |
LRMR Hedge Fund Activity: Q4 2019 in Review
49 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2019, worth a combined $27.7M — up 63% from $17M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LRMR and 13 opened new positions — a net loss of 2 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $1.82M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $1.44M sold.
- 49 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2019, down from 51 in Q3 2019.
- Funds reported $27.7M of Larimar Therapeutics stock for Q4 2019, up 63% quarter-over-quarter.
- 13 funds opened new Larimar Therapeutics positions in Q4 2019 and 15 closed out, a net change of -2 holders.
- The largest Larimar Therapeutics buyer in Q4 2019 was Sio Capital Management, an estimated $1.82M added.
- The largest Larimar Therapeutics seller in Q4 2019 was EcoR1 Capital, an estimated $1.44M sold.
Based on aggregated 13F filings for Q4 2019.